The Australian biotech could potentially be on the hook for more than $1bn after sozinibercept failed to show impact over ...

UNITY anticipates the complete 36-week data results of the remaining patients in the second quarter of 2025.

UBX1325 is a novel BCL-xL inhibitor designed to eliminate senescent cells in diabetic retinal blood vessels, while leaving ...

Unity Biotechnology’s investigational eye treatment failed to match Eylea at 20 weeks—part of the mid-stage trial’s primary ...

Complete 36-week results from the ASPIRE study involving 52 patients are expected in the second quarter of 2025.

Treatment with UBX1325 resulted in vision gains comparable to aflibercept at weeks 24 and 36 in difficult-to-treat patient population UBX1325 was non-inferior to aflibercept at week 24 (>90% confidenc ...

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...